[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Cardiol Therapeutics Inc (CRDL.TO)

Cardiol Therapeutics Inc (CRDL.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])

Fundamentals

See More
  • Market Capitalization, $K 192,505
  • Shares Outstanding, K 115,272
  • Annual Sales, $ 0 K
  • Annual Income, $ -33,819 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta 0.30
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 7.95

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.37 +21.90%
on 07/10/26
1.85 -9.73%
on 07/23/26
+0.18 (+12.08%)
since 06/24/26
3-Month
1.37 +21.90%
on 07/10/26
2.01 -16.92%
on 04/27/26
-0.22 (-11.64%)
since 04/24/26
52-Week
1.23 +35.77%
on 03/20/26
2.33 -28.33%
on 04/22/26
-0.25 (-13.02%)
since 07/24/25

Most Recent Stories

More News
Stocks in play: Cardiol Therapeutics Inc.

Announced the publication of its Phase II MAvERIC study results in the Journal of the American Heart ...

CRDL.TO : 1.67 (-4.02%)
Cardiol Therapeutics' Phase II Recurrent Pericarditis Data Published in the Journal of the American Heart Association

• Peer-reviewed JAHA publication strengthens the foundation for Cardiol's pivotal Phase III MAVERIC trial as enrollment nears completion.

CRDL.TO : 1.67 (-4.02%)
CRDL : 1.1800 (-4.07%)
Cardiol Therapeutics' Phase II Recurrent Pericarditis Data Published in the Journal of the American Heart Association

• Peer-reviewed JAHA publication strengthens the foundation for Cardiol's pivotal Phase III MAVERIC trial as enrollment nears completion.

CRDL.TO : 1.67 (-4.02%)
CRDL : 1.1800 (-4.07%)
Cardiol Therapeutics to Participate in Fireside Chat at B. Riley Securities Mind, Muscle & Vision Summit

TORONTO , July 9, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (" Cardiol " or the " Company "), a late-stage life sciences company advancing anti-inflammatory...

CRDL.TO : 1.67 (-4.02%)
CRDL : 1.1800 (-4.07%)
Stocks in play: Cardiol Therapeutics Inc.

Announces the results from its Annual General Meeting of Shareholders held virtually via live audio ...

CRDL.TO : 1.67 (-4.02%)
Cardiol Therapeutics Reports Results of 2026 Annual General Meeting of Shareholders

TORONTO , June 25, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic...

CRDL.TO : 1.67 (-4.02%)
CRDL : 1.1800 (-4.07%)
Cardiol Therapeutics Reports Results of 2026 Annual General Meeting of Shareholders

TORONTO , June 25, 2026 /CNW/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic...

CRDL.TO : 1.67 (-4.02%)
CRDL : 1.1800 (-4.07%)
Stocks in play: Cardiol Therapeutics Inc.

Announces that the Company's virtual Annual General Meeting of Shareholders will be webcast on June ...

CRDL.TO : 1.67 (-4.02%)
Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on June 24th at 4:30 p.m. EDT

TORONTO , June 23, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic...

CRDL.TO : 1.67 (-4.02%)
CRDL : 1.1800 (-4.07%)
Stocks in play: Cardiol Therapeutics Inc.

Will participate in a Fireside Chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference ...

CRDL.TO : 1.67 (-4.02%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation...

See More

Key Turning Points

3rd Resistance Point 1.83
2nd Resistance Point 1.78
1st Resistance Point 1.73
Last Price 1.67
1st Support Level 1.63
2nd Support Level 1.58
3rd Support Level 1.53

See More

52-Week High 2.33
Fibonacci 61.8% 1.91
Fibonacci 50% 1.78
Last Price 1.67
Fibonacci 38.2% 1.65
52-Week Low 1.23

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.